The FDA previously granted selpercatinib (LOXO-292) accelerated approval in 2020 for RET fusion–positive metastatic NSCLC, excitingly, Selpercatinib was authorized by the FDA as first-line regular therapy for RET fusion-positive advanced or metastatic NSCLC in Nov 2022 (11). This evidence concerns the gene RET and non-small cell lung carcinoma.